PRINCETON, N.J., March 20 /PRNewswire-FirstCall/ -- China Biopharma, Inc. , a biopharmaceutical company, announced today that its Chinese subsidiary, Hainan CITIC Biopharmaceutical Development Co., Ltd., has entered into a distribution agreement with Takeda Pharmaceutical Company, Ltd. (“Takeda”), the largest pharmaceutical company in Japan. With world headquarters located in Oska, Japan, Takeda specializes in the research and development of breakthrough drugs, and has marketing operations throughout U.S., Europe, and Asia. In Japan, Takeda has also built a strong presence in the over-the-counter (OTC) drug market, in which it holds the second largest domestic share.
Takeda has a robust pipeline with compounds in development for diabetes, cardiovascular disease and other conditions. As part of Takeda’s goal to expand sales channels in Asia, China Biopharma has begun distributing Serrapeptase tablets, and the agreement with Takeda calls for China Biopharma to distribute additional drugs as they become available.
Wang Qiumen, General Manager of Hainan CITIC Pharmaceutical, commented, “Takeda is an internationally-renowned pharmaceutical company that offers China Biopharma tremendous new growth opportunities. This agreement marks a new milestone in our product diversification strategy. We are focused on adding products that can create steady and robust revenue streams year-round, and that can more than offset seasonal product sales such as our flu vaccines. Pharmaceuticals represent a high-growth, lucrative market that can serve large populations throughout China, and we are very excited to enter this market in the present quarter.”
About Takeda
Takeda Pharmaceutical Company, Ltd. is a research-based global company with its main focus on pharmaceuticals. It is the largest pharmaceutical company in Japan and among the leaders in the world. Takeda discovers, develops, manufactures and markets a broad range of superior pharmaceutical products to strive toward better health for individuals and progress in medicine. For more information, visit www.takeda.com.
About China Biopharma Inc.
China Biopharma Inc. is a fast-growing biopharmaceutical company based in China. Through its operating subsidiaries, the Company develops and distributes human vaccine products throughout the world’s most populated country, China. Products include human vaccines against influenza, hemorrhagic fever, and Japanese Encephalitis. Leveraging its investment and ownership of local Chinese biopharmaceutical companies, and partnerships with international vaccine providers, China Biopharma is building a highly-competitive platform for growth in China as well as new markets, including the U.S. and Europe. For more information, visit its website at http://www.chinabiopharma.com.cn.
Safe Harbor Statement
Some of the statements made in this press release discuss future events and developments, including the Company’s future business strategy and its ability to generate revenue, income and cash flow, and should be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These “forward-looking” statements can generally be identified by words such as “expect,” “anticipate,” “believe,” “estimate,” “intend,” “plan,” and similar expressions. These statements involve a high degree of risk and uncertainty that exists in the Company’s operations and business environment and are subject to change based on various factors that could cause actual Company results, performance, plans, goals and objectives to differ materially from those contemplated or implied in these forward-looking statements. Actual results may be different from anticipated results for a number of reasons, including the Company’s new and uncertain business model, uncertainty regarding acceptance of the Company’s products and services and the Company’s limited operating history.
CONTACT: At the Company: George Ji China Biopharma, Inc. Tel: +1 (609) 651-8588 ir@chinabiopharma.nethttp://www.chinabiopharma.com.cn Investor Relations: OTC Financial Network Peter Clark Tel: +1 (781) 444-6100x629 peter@otcfn.com
China Biopharma, Inc.
CONTACT: George Ji of China Biopharma, Inc., +1-609-651-8588, orir@chinabiopharma.net; or Investor Relations, Peter Clark of OTC FinancialNetwork, +1-781-444-6100 x629, or peter@otcfn.com
